You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letters
Author's response: Outcomes of polypoidal choroidal vasculopathy treated with ranibizumab monotherapy
  1. Taiichi Hikichi
  1. Correspondence to Dr Taiichi Hikichi, Department of Ophthalmology, Ohtsuka Eye Hospital, Kita-16 Nishi-4, Kita-ku, Sapporo 001-0016, Japan; taiichi-hikichi{at}hokkaido.med.or.jp

https://doi.org/10.1136/bjophthalmol-2013-304688

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    I thank Dr Tan and associates for their comments1 regarding my article entitled ‘Results of 2 years of treatment with as-needed ranibizumab reinjection for polypoidal choroidal vasculopathy (PCV)’,2 and welcome the opportunity to discuss treatment of PCV. In their comments, Dr Tan and associates pointed out the apparently higher regression rate of polypoidal lesions after photodynamic therapy (PDT) compared with ranibizumab (Lucentis, Genentech, South San Francisco, California, USA) monotherapy and emphasised the important implication of regression of polypoidal lesions in the outcomes of treatment for PCV.

    The EVEREST study,3 a randomised controlled trial of PDT alone or in combination with ranibizumab compared with ranibizumab monotherapy for PCV, concluded that PDT is more effective than ranibizumab for achieving regression of …

    View Full Text

    Footnotes

    • Contributors Literature review and formulation of the manuscript: TH.

    • Competing interests None.

    • Provenance and peer review Not commissioned; externally peer reviewed.